Dr. Susannah Tye, a researcher within the Mayo Clinic Department of Psychiatry and Psychology, discusses research on optimizing depression treatment with ketamine intervention for patients with treatment-resistant depression.
Young people suffering from treatment-resistant depression (TRD) showed a significant reduction of their symptoms after being administered ketamine infusions, according to a study published in the Journal of Child and Adolescent Psychopharmacology.
Intravenous ketamine infusions have been used extensively to treat often-intractable neuropathic pain conditions. Because there are many widely divergent ketamine infusion protocols described in the literature, the variation in these protocols presents a challenge for direct comparison of one protocol with another and in discerning an optimal protocol.
A team at the University of Illinois at Chicago has uncovered a new mechanism that helps explain the remarkably rapid, and long-lasting, antidepressant effects of the controversial drug ketamine. The exciting research reveals the drug operates in a similar way to conventional SSRI antidepressants, except is it significantly more effective.
An analysis of data from the FDA Adverse Events Reporting System (FAERS) supported previous findings that ketamine could be an effective treatment for depression, researchers found.
For six years now, life has been really good for James. He has a great job as the creative director of an advertising firm in New York City. He enjoys spending time with his wife and kids.
STARTING A KETAMINE CLINIC
The demand for ketamine infusion therapy is growing at an exponential rate. As the mounting research supports the use of ketamine infusions for treatment resistant depression and other mental health disorders, as well as multiple forms of chronic neuropathic pain, increasingly, patients are opening their minds to the hope behind ketamine infusions. By becoming a ketamine provider, you can bring this hope to those suffering from these debilitating mental and physical conditions—while also establishing a successful business.
More than three million Americans report suffering from clinical depression each year — and according to the National Institute of Mental Health, more than 16 million Americans experienced at least one major depressive episode in 2016. That number makes up almost seven percent of all adults in the country.
- Ketamine is emerging as a potential new drug for depression — the first of its kind in 35 years.
- Johnson & Johnson is actively pursuing a nasal formulation of the drug. Researchers plan to present the results of an advanced clinical trial of the formula next month at the American Psychiatric Association meeting.
- An early glimpse at some of the results suggests that the formula is safe and linked with sustained improvements in depressive symptoms over a year.